⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269738 | 0.69 | — | — | |
| SCHEMBL2963 | 0.69 | — | — | |
| SCHEMBL1565376 | 0.69 | — | — | |
| SCHEMBL5161198 | 0.68 | — | — | |
| SCHEMBL6200536 | 0.65 | GSK3A (0.33) | — | |
| SCHEMBL16837105 | 0.61 | — | — | |
| SCHEMBL3370761 | 0.60 | — | — | |
| SCHEMBL1555131 | 0.60 | — | — | |
| SCHEMBL6497343 | 0.59 | — | — | |
| SCHEMBL3700211 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951725-B1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | ABBOTT PRODUCTS GMBH (DE) | 2010-11-03 | — | — | EP | claimed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | claimed |
| EP-1951725-A1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | Solvay Pharmaceuticals GmbH (DE) | 2008-08-06 | — | — | EP | claimed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | claimed |
| WO-2007054580-A1 | N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| JP-2007506716-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | claimed |
| EP-1670786-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030757-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-10100048-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-16 | — | — | US | disclosed |
| EP-2621914-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2016-12-28 | — | — | EP | disclosed |
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2016-07-07 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1670786-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030757-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |